Madrid, Spain
October 23-27
Booth #1021
Connect with Caris Life Sciences at the ESMO Congress 2026
Join Caris Life Sciences® at ESMO 2026 in Madrid, Spain. Visit our team at booth #1021 to discover the latest innovations in precision medicine and explore new Caris research.
Every Patient with Cancer Deserves Complete Answers
Caris helps physicians make more informed treatment decisions throughout the cancer care journey by providing high-quality molecular information to guide precise and individualized treatment decisions.
Learn more about how Caris testing can provide more actionable targets for more informed decisions to support more personalized care. Schedule time to meet with our team during ESMO by completing the request form.
Presenting New Caris Life Sciences Research at ESMO Congress 2026
Caris and collaborators from leading cancer centers — including those within the Caris Precision Oncology Alliance® (POA®) — will collectively present eight posters covering a wide range of tumor types:
Saturday, October 24
- 3285P – Characterization of G-protein coupled estrogen receptor (GPER) and estrogen receptor in EGFR-mutated NSCLC leading to survival differences
- 4395P – A 25-gene T-cell exhaustion signature refines TLS-based prediction of immunotherapy benefit
- 2136P – Site-dependent stromal-mesenchymal reprogramming associated with survival and immunotherapy outcomes in BAP1-mutant uveal melanoma (UM)
Sunday, October 25
- 178P – Caris CapeAI, An Artificial Intelligence Model of ER+ Breast Cancer Response to Capecitabine
- 217P – Toward Precision Extended Endocrine Therapy in Early HR+ Breast Cancer: Multimodal AI for Risk and Benefit Stratification
Monday, October 26
- 1296P – Genomic Scar–Defined Homologous Recombination Deficiency (HRD) and Tumor Immune Microenvironment in Endometrial Cancer (EC)
- 2681P – Characterization of differences across Organ Site Specific Metastasis in NSCLC by Race/Ethnicity
- 2686P – RRAS2mt Non-small cell lung cancer (NSCLC) defines a distinct subset of RASmt NSCLC
Schedule a Meeting
Products At-a-Glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure® delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Profile
Comprehensive profiling assesses DNA, RNA and Proteins from tumor tissue to reveal a more complete molecular blueprint that helps guide precise and individualized treatment decisions. Tests include next-generation sequencing (NGS), immunohistochemistry (IHC), chromogenic in situ hybridization (CISH), pyrosequencing, and AI-predictive algorithms for select tumor types.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.